Provaris Energy Ltd (ASX:PV1, OTC:GBBLF, FRA:WS90) has completed a $1 million placement to support key 2026 technical ...
ATAI also has VLS-01, which gives it a nearer-term Q4 2026 TRD catalyst. EMP-01 adds some optionality in social anxiety ...
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today provides shareholders a ...
St. Louis will host July workshops and a virtual meeting to present draft zoning development standards, share map updates, ...
State auditor: Iowa taxpayers spent $258 million on private school tuition ...
Oversubscribed $225 million concurrent private investment in public equity ("PIPE") with available cash to the combined ...
LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive ...
PARP inhibitors reshaped oncology when they first reached patients some 10 years ago, but they represent just one entry point into a much larger and more intricate biological network.
The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera's plan to submi ...
Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) ("Biodexa” or the "Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with ...
A new generation of reversible male contraceptives is advancing through clinical trials to expand family planning options.
The new agreement creates more competition but could leave officials "looking over their shoulders." ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results